AstraZeneca’s CALQUENCE® (acalabrutinib) together with venetoclax, with or with out obinutuzumab, has proven vital enchancment in progression-free survival in comparison with customary chemoimmunotherapy in beforehand untreated persistent lymphocytic leukemia (CLL) sufferers. The AMPLIFY Part III trial additionally demonstrated a favorable pattern in general survival. CLL, the most typical grownup leukemia, impacts roughly 40,000 first-line sufferers yearly. The trial outcomes recommend CALQUENCE’s potential as each a treat-to-progression and fixed-duration remedy, providing extra choices for sufferers and healthcare suppliers. The protection profile was per identified knowledge, displaying low charges of cardiac toxicity. These findings reinforce AstraZeneca’s management in CLL remedy developments.
CALQUENCE® (acalabrutinib) di AstraZeneca, in combinazione con venetoclax, con o senza obinutuzumab, ha mostrato un miglioramento significativo della sopravvivenza libera da progressione rispetto alla chemioterapia immunologica customary nei pazienti con leucemia linfatica cronica (LLC) non precedentemente trattati. Lo studio di fase III AMPLIFY ha anche dimostrato una tendenza favorevole nella sopravvivenza complessiva. La LLC, la leucemia più comune negli adulti, colpisce circa 40.000 pazienti in prima linea annualmente. I risultati dello studio suggeriscono il potenziale di CALQUENCE come trattamento fino alla progressione e trattamento a durata fissa, offrendo maggiori opzioni per i pazienti e per i fornitori di assistenza sanitaria. Il profilo di sicurezza è risultato coerente con i dati noti, mostrando bassi tassi di tossicità cardiaca. Questi risultati rafforzano la management di AstraZeneca nei progressi nel trattamento della LLC.
CALQUENCE® (acalabrutinib) de AstraZeneca, en combinación con venetoclax, con o sin obinutuzumab, ha mostrado una mejora significativa en la supervivencia libre de progresión en comparación con la quimioinmunoterapia estándar en pacientes con leucemia linfocítica crónica (LLC) no tratados previamente. El estudio de fase III AMPLIFY también demostró una tendencia favorable en la supervivencia common. La LLC, la leucemia más común en adultos, afecta a aproximadamente 40,000 pacientes de primera línea anualmente. Los resultados del ensayo sugieren el potencial de CALQUENCE como un tratamiento hasta la progresión y tratamiento de duración fija, ofreciendo más opciones para los pacientes y proveedores de atención médica. El perfil de seguridad fue consistente con los datos conocidos, mostrando bajas tasas de toxicidad cardíaca. Estos hallazgos refuerzan el liderazgo de AstraZeneca en los avances del tratamiento de la LLC.
AstraZeneca의 CALQUENCE® (acalabrutinib)는 venetoclax와 함께 또는 obinutuzumab 없이 사용했을 때, 이전에 치료받지 않은 만성 림프구성 백혈병(CLL) 환자들에게 표준 화학면역요법에 비해 질병 진행 없는 생존율의 유의한 개선을 보여주었습니다. AMPLIFY 3상 시험은 또한 전체 생존율에서 유리한 경향을 나타냈습니다. CLL은 성인에서 가장 흔한 백혈병으로, 매년 약 40,000명의 1차 환자에게 영향을 미칩니다. 시험 결과는 CALQUENCE의 진행까지의 치료 및 고정 기간 치료로서의 가능성을 제시하여, 환자와 의료 제공자에게 더 많은 옵션을 제공합니다. 안전 프로필은 알려진 데이터와 일치하며, 저렴한 심장 독성 비율을 나타냈습니다. 이러한 발견은 CLL 치료 발전에 있어 AstraZeneca의 리더십을 강화합니다.
CALQUENCE® (acalabrutinib) d’AstraZeneca, en affiliation avec venetoclax, avec ou sans obinutuzumab, a montré une amélioration significative de la survie sans development par rapport à la chimiothérapie immunologique customary chez des sufferers atteints de leucémie lymphoïde chronique (LLC) non traités auparavant. L’essai de section III AMPLIFY a également démontré une tendance favorable à la survie globale. La LLC, la leucémie la plus courante chez les adultes, touche environ 40 000 sufferers en première ligne chaque année. Les résultats de l’essai suggèrent le potentiel de CALQUENCE en tant que traitement jusqu’à la development et traitement de durée fixe, offrant plus d’choices pour les sufferers et les prestataires de soins de santé. Le profil de sécurité était cohérent avec les données connues, montrant de faibles taux de toxicité cardiaque. Ces résultats renforcent le management d’AstraZeneca dans les avancées du traitement de la LLC.
CALQUENCE® (acalabrutinib) von AstraZeneca, in Kombination mit Venetoclax, mit oder ohne Obinutuzumab, hat eine signifikante Verbesserung des progressionsfreien Überlebens im Vergleich zur Commonplace-Chemotherapie in bisher unbehandelten Patienten mit chronischer lymphatischer Leukämie (CLL) gezeigt. Die AMPLIFY-Part-III-Studie zeigte außerdem einen günstigen Development in der Gesamtüberlebensrate. Die CLL, die häufigste Leukämie bei Erwachsenen, betrifft jährlich etwa 40.000 Patienten in der ersten Linie. Die Studienergebnisse deuten auf das Potenzial von CALQUENCE als Behandlung bis zur Development und Behandlung mit fester Dauer hin, was den Patienten und Gesundheitsdienstleistern mehr Optionen bietet. Das Sicherheitsprofil struggle konsistent mit bekannten Daten und zeigte niedrige Raten von kardialer Toxizität. Diese Ergebnisse stärken die Führungsrolle von AstraZeneca bei den Fortschritten in der CLL-Behandlung.
Optimistic
- Statistically vital enchancment in progression-free survival for CALQUENCE mixture remedy
- Favorable pattern noticed in general survival
- Potential for CALQUENCE for use as each treat-to-progression and fixed-duration remedy
- Low charges of cardiac toxicity noticed
- Security and tolerability per identified security profile of every medication
Adverse
- Total survival knowledge not mature on the time of study
The AMPLIFY Part III trial outcomes for CALQUENCE® (acalabrutinib) together with venetoclax, with or with out obinutuzumab, symbolize a vital development in persistent lymphocytic leukemia (CLL) remedy. The examine demonstrated a statistically vital and clinically significant enchancment in progression-free survival (PFS) in comparison with customary chemoimmunotherapy in beforehand untreated CLL sufferers.
Key factors to contemplate:
- The fixed-duration routine confirmed promise, doubtlessly permitting sufferers to take breaks from remedy, which might scale back long-term hostile occasions and drug resistance.
- A positive pattern in general survival was noticed, although knowledge weren’t mature on the time of study.
- The protection profile was per identified profiles of the person medicines, with low charges of cardiac toxicity – a vital issue for CLL sufferers who are sometimes older and will have comorbidities.
- If authorized, CALQUENCE would turn out to be the solely second-generation BTK inhibitor accessible as each a treat-to-progression and fixed-duration remedy, providing extra flexibility for sufferers and healthcare suppliers.
From an investor’s perspective, these outcomes might doubtlessly broaden CALQUENCE’s market share within the aggressive CLL remedy panorama. Nevertheless, it is vital to notice that full approval will depend upon additional knowledge and regulatory overview.
The optimistic outcomes from the AMPLIFY Part III trial for CALQUENCE® might have vital monetary implications for AstraZeneca:
- Market Growth: If authorized for this new mixture remedy, CALQUENCE might seize a bigger share of the CLL market, which is substantial with roughly
40,000 first-line sufferers handled yearly. - Aggressive Benefit: Being doubtlessly the one second-generation BTK inhibitor accessible as each a treat-to-progression and fixed-duration remedy might differentiate CALQUENCE from opponents, doubtlessly driving elevated adoption and gross sales.
- Income Progress: Expanded indications and remedy choices might result in elevated prescriptions and income. In 2023, CALQUENCE generated
2.17 billion in international income, up20% from the earlier 12 months. - R&D Funding Payoff: These outcomes validate AstraZeneca’s funding in oncology R&D, notably in hematology, which might increase investor confidence within the firm’s pipeline and technique.
Nevertheless, traders ought to take into account:
- Regulatory approval remains to be pending and full knowledge presentation is but to come back.
- The aggressive panorama in CLL remedy is intense, with different main gamers additionally growing new therapies.
- Pricing and reimbursement negotiations will probably be vital for market entry and profitability.
Total, this information is prone to be considered positively by the market, doubtlessly supporting AstraZeneca’s inventory efficiency within the close to time period.
Favorable pattern in general survival was additionally noticed
Optimistic high-level outcomes from an interim evaluation of the AMPLIFY Part III trial confirmed a hard and fast length of AstraZeneca’s CALQUENCE® (acalabrutinib) together with venetoclax, with or with out obinutuzumab, demonstrated a statistically vital and clinically significant enchancment in progression-free survival (PFS) in comparison with standard-of-care chemoimmunotherapy in beforehand untreated grownup sufferers with persistent lymphocytic leukemia (CLL).
For the secondary endpoint of general survival (OS), a pattern was noticed in favor of CALQUENCE together with venetoclax, with or with out obinutuzumab, versus standard-of-care chemoimmunotherapy. The OS knowledge weren’t mature on the time of this evaluation and the trial will proceed to evaluate OS as a key secondary endpoint.
CLL is attributable to the irregular manufacturing of white blood cells and is essentially the most prevalent kind of leukemia in adults worldwide, with numbers anticipated to develop.1-3 Within the first-line setting, roughly 40,000 sufferers are handled with the present customary of care.4 Though CLL is taken into account an incurable most cancers, sufferers typically stay with the illness for a few years, and will stay on steady remedy.5
Jennifer R. Brown, MD, PhD, Director of the CLL Middle of the Division of Hematologic Malignancies, Dana-Farber Most cancers Institute, and the Worthington and Margaret Collette Professor of Medication at Harvard Medical College, and principal investigator of the trial, stated: “The AMPLIFY outcomes exhibit the potential of acalabrutinib and venetoclax with or with out obinutuzumab to be efficient and well-tolerated fixed-duration remedy choices for sufferers with persistent lymphocytic leukemia. This is a crucial advance on this setting as fixed-duration regimens enable these dwelling with this persistent illness to take breaks from their remedy, thereby lowering the potential of long-term hostile occasions and drug resistance and bettering high quality of life.”
Susan Galbraith, Govt Vice President, Oncology R&D, AstraZeneca, stated: “The progression-free survival and general survival outcomes from the AMPLIFY Part III trial exhibit the potential of together with a BTK inhibitor in a fixed-duration routine and reinforce our management in advancing science for sufferers with persistent lymphocytic leukemia. If authorized, CALQUENCE would turn out to be the one second-generation BTK inhibitor accessible as each a treat-to-progression and fixed-duration remedy, offering extra choices for sufferers and their healthcare suppliers.”
The protection and tolerability have been per the identified security profile of every medication. No new security indicators have been recognized, with low charges of cardiac toxicity noticed.
The information will probably be offered at a forthcoming medical assembly and shared with international regulatory authorities.
INDICATIONS AND USAGE
CALQUENCE is a Bruton tyrosine kinase (BTK) inhibitor indicated for the remedy of grownup sufferers with mantle cell lymphoma (MCL) who’ve acquired at the very least one prior remedy.
This indication is authorized beneath accelerated approval based mostly on general response charge. Continued approval for this indication could also be contingent upon verification and outline of medical profit in confirmatory trials.
CALQUENCE can also be indicated for the remedy of grownup sufferers with persistent lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
IMPORTANT SAFETY INFORMATION ABOUT CALQUENCE® (acalabrutinib) tablets
Severe and Opportunistic Infections
Deadly and critical infections, together with opportunistic infections, have occurred in sufferers with hematologic malignancies handled with CALQUENCE.
Severe or Grade 3 or larger infections (bacterial, viral, or fungal) occurred in
Hemorrhage
Deadly and critical hemorrhagic occasions have occurred in sufferers with hematologic malignancies handled with CALQUENCE. Main hemorrhage (critical or Grade 3 or larger bleeding or any central nervous system bleeding) occurred in
Use of antithrombotic brokers concomitantly with CALQUENCE might additional improve the danger of hemorrhage. In medical trials, main hemorrhage occurred in
Think about the benefit-risk of withholding CALQUENCE for 3-7 days pre- and post-surgery relying upon the kind of surgical procedure and the danger of bleeding.
Cytopenias
Grade 3 or 4 cytopenias, together with neutropenia (
Second Main Malignancies
Second main malignancies, together with pores and skin cancers and different strong tumors, occurred in
Cardiac Arrhythmias
Severe cardiac arrhythmias have occurred in sufferers handled with CALQUENCE. Grade 3 atrial fibrillation or flutter occurred in
Hepatotoxicity, Together with Drug-Induced Liver Harm
Hepatotoxicity, together with extreme, life-threatening, and doubtlessly deadly circumstances of drug-induced liver harm (DILI), has occurred in sufferers handled with Bruton tyrosine kinase inhibitors, together with CALQUENCE.
Consider bilirubin and transaminases at baseline and all through remedy with CALQUENCE. For sufferers who develop irregular liver checks after CALQUENCE, monitor extra ceaselessly for liver take a look at abnormalities and medical indicators and signs of hepatic toxicity. If DILI is suspected, withhold CALQUENCE. Upon affirmation of DILI, discontinue CALQUENCE.
ADVERSE REACTIONS
The commonest hostile reactions (≥
*Remedy-emergent decreases (all grades) of hemoglobin (
Dose reductions or discontinuations as a result of any hostile response have been reported in
The commonest hostile reactions (≥
*Remedy-emergent decreases (all grades) of hemoglobin, platelets, and neutrophils have been based mostly on laboratory measurements and hostile reactions.
In sufferers with beforehand untreated CLL uncovered to CALQUENCE, deadly hostile reactions that occurred within the absence of illness development and with onset inside 30 days of the final examine remedy have been reported in
Antagonistic reactions led to CALQUENCE dose discount in
In sufferers with relapsed/refractory CLL uncovered to CALQUENCE, critical hostile reactions occurred in
Antagonistic reactions led to CALQUENCE dose discount in
DRUG INTERACTIONS
Robust CYP3A Inhibitors: Keep away from co-administration of CALQUENCE with a robust CYP3A inhibitor. If these inhibitors will probably be used short-term, interrupt CALQUENCE. After discontinuation of sturdy CYP3A inhibitor for at the very least 24 hours, resume earlier dosage of CALQUENCE.
Reasonable CYP3A Inhibitors: Cut back the dosage of CALQUENCE to 100 mg as soon as day by day when co-administered with a average CYP3A inhibitor.
Robust CYP3A Inducers: Keep away from co-administration of CALQUENCE with a robust CYP3A inducer. If co-administration is unavoidable, improve the dosage of CALQUENCE to 200 mg roughly each 12 hours.
SPECIFIC POPULATIONS
Primarily based on findings in animals, CALQUENCE might trigger fetal hurt and dystocia when administered to a pregnant girl. There aren’t any accessible knowledge in pregnant ladies to tell the drug-associated threat. Advise pregnant ladies of the potential threat to a fetus.
Being pregnant testing is really useful for females of reproductive potential previous to initiating CALQUENCE remedy. Advise feminine sufferers of reproductive potential to make use of efficient contraception throughout remedy with CALQUENCE and for 1 week following the final dose of CALQUENCE.
It isn’t identified if CALQUENCE is current in human milk. Advise lactating ladies to not breastfeed whereas taking CALQUENCE and for two weeks after the final dose.
Keep away from use of CALQUENCE in sufferers with extreme hepatic impairment (Youngster-Pugh class C). No dosage adjustment of CALQUENCE is really useful in sufferers with delicate (Youngster-Pugh class A) or average (Youngster-Pugh class B) hepatic impairment.
Please see full Prescribing Info, together with Affected person Info.
Notes
CLL
In CLL, there’s an accumulation of irregular lymphocytes inside the bone marrow and in blood and lymph nodes.1 Though some folks with CLL might not expertise any signs at prognosis, others might expertise signs, corresponding to weak point, fatigue, weight reduction, chills, fever, evening sweats, swollen lymph nodes and belly ache.6 Because the variety of irregular cells will increase, there’s much less room inside the marrow for the manufacturing of regular white blood cells, crimson blood cells and platelets. This might lead to anemia, an infection and bleeding.1 B-cell receptor signaling by way of BTK is among the important survival pathways for CLL.
AMPLIFY
AMPLIFY is a randomized, international, multi-center, open-label Part III trial evaluating the efficacy and security of CALQUENCE together with venetoclax with and with out obinutuzumab in comparison with investigator’s alternative of chemoimmunotherapy in grownup sufferers with beforehand untreated CLL with out del(17p) or TP53 mutation.7 Sufferers have been randomized 1:1:1 to obtain both CALQUENCE together with venetoclax, CALQUENCE together with venetoclax plus obinutuzumab for a hard and fast length or standard-of-care chemoimmunotherapy.7
The first endpoint is PFS within the CALQUENCE and venetoclax arm as assessed by an Impartial Evaluate Committee (IRC) and PFS on this arm assessed by investigators (INV) is a key secondary endpoint. IRC and INV assessed PFS within the CALQUENCE, venetoclax and obinutuzumab arm as a key secondary endpoint. Different key secondary endpoints embody OS, event-free survival, general response charge, length of response and time to subsequent remedy.7 The trial contains 27 nations throughout
The AMPLIFY trial enrolled sufferers from 2019 to 2021, persevering with by way of the COVID-19 pandemic.7 Sufferers with blood most cancers stay at a disproportionately excessive threat of extreme outcomes from COVID-19, together with hospitalization and demise in comparison with the final inhabitants.8
CALQUENCE
CALQUENCE (acalabrutinib) is a second-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK). CALQUENCE binds covalently to BTK, thereby inhibiting its exercise.9 In B-cells, BTK signaling leads to activation of pathways essential for B-cell proliferation, trafficking, chemotaxis and adhesion.
CALQUENCE has been used to deal with greater than 80,000 sufferers worldwide10 and is authorized for the remedy of CLL and small lymphocytic lymphoma (SLL) within the US and
As a part of an intensive medical improvement program, CALQUENCE is presently being evaluated as a single remedy and together with standard-of-care chemoimmunotherapy for sufferers with a number of B-cell blood cancers, together with CLL, MCL and diffuse giant B-cell lymphoma.
AstraZeneca in hematology
AstraZeneca is pushing the boundaries of science to redefine care in hematology. Our objective is to assist rework the lives of sufferers dwelling with malignant, uncommon and different associated hematologic illnesses by way of progressive medicines and approaches which are formed by insights from sufferers, caregivers and physicians.
Along with our marketed merchandise, we’re spearheading the event of novel therapies designed to focus on underlying drivers of illness throughout six scientific platforms. Our current acquisitions of Alexion, with experience in uncommon, non-malignant blood problems, and Gracell Biotechnologies Inc., targeted on cell therapies for hematologic malignancies, broaden our hematology pipeline and allow us to succeed in extra sufferers with excessive unmet wants by way of the end-to-end improvement and supply of novel therapies.
AstraZeneca in oncology
AstraZeneca is main a revolution in oncology with the ambition to offer cures for most cancers in each type, following the science to grasp most cancers and all its complexities to find, develop and ship life-changing medicines to sufferers.
The Firm’s focus is on a few of the most difficult cancers. It’s by way of persistent innovation that AstraZeneca has constructed one of the various portfolios and pipelines within the business, with the potential to catalyze adjustments within the observe of medication and rework the affected person expertise.
AstraZeneca has the imaginative and prescient to redefine most cancers care and, at some point, remove most cancers as a explanation for demise.
AstraZeneca
AstraZeneca is a worldwide, science-led biopharmaceutical firm that focuses on the invention, improvement and commercialization of prescription medicines in Oncology, Uncommon Illnesses and BioPharmaceuticals, together with Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Primarily based in
References
- Nationwide Most cancers Institute. Continual Lymphocytic Leukemia Remedy (PDQ®)–Affected person Model: Normal Info About Continual Lymphocytic Leukemia. Obtainable on-line. Accessed July 2024.
- American Most cancers Society. What’s Continual Lymphocytic Leukemia? Obtainable on-line. Accessed July 2024.
- Jain N, et al. Prevalence and Financial Burden of Continual Lymphocytic Leukemia (CLL) within the Period of Oral Focused Therapies. Blood. 2015;126(23):871.
-
Cerner CancerMPact and DRG databases. Displays epidemiology estimates throughout G8 nations (Cerner CancerMPact for G7: US, EU,
Japan ; DRG database forChina ). Accessed July 2024. - American Most cancers Society. After Continual Lymphocytic Leukemia Remedy. Obtainable at: https://www.most cancers.org/most cancers/sorts/chronic-lymphocytic-leukemia/after-treatment/follow-up. Accessed July 2024.
- American Most cancers Society. Indicators and Signs of Continual Lymphocytic Leukemia. Obtainable on-line. Accessed July 2024.
- ClinicalTrials.gov. Examine of Acalabrutinib (ACP-196) in Mixture With Venetoclax (ABT-199), With and With out Obinutuzumab (GA101) Versus Chemoimmunotherapy for Beforehand Untreated CLL (AMPLIFY). Obtainable at: https://clinicaltrials.gov/examine/NCT03836261. Accessed July 2024.
-
Dube S, et al. Continued Elevated Danger of COVID-19 Hospitalisation and Demise in Immunocompromised People Regardless of Receipt of ≥4 Vaccine Doses: Up to date 2023 Outcomes from INFORM, a Retrospective Well being Database Examine in
England . Poster P0409 at ECCMID 2024. - Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(21).
- Information on File, REF-236261. AstraZeneca Prescribed drugs LP.
US-92135 Final Up to date 7/24
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240729312862/en/
Media Inquiries
Brendan McEvoy +1 302 885 2677
US Media Mailbox: usmediateam@astrazeneca.com
Supply: AstraZeneca
FAQ
What have been the important thing outcomes of the AMPLIFY Part III trial for CALQUENCE (AZN)?
The AMPLIFY Part III trial confirmed that CALQUENCE together with venetoclax, with or with out obinutuzumab, considerably improved progression-free survival in comparison with customary chemoimmunotherapy in beforehand untreated CLL sufferers. A positive pattern in general survival was additionally noticed.
How does the AMPLIFY trial end result influence remedy choices for CLL sufferers?
The outcomes recommend that CALQUENCE might turn out to be the one second-generation BTK inhibitor accessible as each a treat-to-progression and fixed-duration remedy, offering extra choices for CLL sufferers and their healthcare suppliers.
What was the security profile of CALQUENCE within the AMPLIFY trial?
The protection and tolerability have been per the identified security profile of every medication. No new security indicators have been recognized, and low charges of cardiac toxicity have been noticed.
When will AstraZeneca (AZN) current the complete AMPLIFY trial knowledge?
AstraZeneca plans to current the complete AMPLIFY trial knowledge at a forthcoming medical assembly and share the outcomes with international regulatory authorities.